Trial Profile
Ascending Multi-Dose Clinical Trial to Assess the Pharmacokinetics Efficacy of SM-88 Oral Administration in Breast Cancer Subjects
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 04 Jul 2022
Price :
$35
*
At a glance
- Drugs Racemetyrosine (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Synergy Pharmaceuticals Inc; Tyme Technologies
- 28 Jun 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 04 Mar 2021 Planned End Date changed from 1 Oct 2019 to 1 Oct 2023.
- 04 Mar 2021 Planned primary completion date changed from 1 Oct 2019 to 1 Oct 2023.